9604.Se
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
Business. The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
The company maintains a strong liquidity position, with a current ratio of 5.5, indicating a robust ability to meet short-term obligations. Its liquidity is further supported by cash and equivalents of 18,107,340, which provides a buffer against short-term liabilities. The company's debt-to-equity ratio of 0.21 suggests a conservative capital structure, with a relatively low proportion of debt financing compared to equity.
In terms of profitability, the company demonstrates a return on equity of 23.65% and a return on assets of 17.15%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures suggest the company is performing well relative to industry standards. The operating margin, calculated as operating income divided by revenue, is 22.78%, which is a key metric for assessing operational efficiency.
The company's revenue is concentrated within its core operations, with no significant geographic diversification reported. This concentration may pose a risk if the company's primary market experiences economic downturns or regulatory changes. The company's revenue is primarily derived from its biotechnology and healthcare services segments, with no material diversification across other business lines.
The company's growth trajectory is positive, with a strong operating cash flow of 25,258,310 and a free cash flow of 17,831,350, indicating the ability to fund operations and invest in future growth. The capital expenditure of -7,358,840 suggests that the company is not currently investing heavily in new assets, which may indicate a focus on maintaining existing operations rather than expansion.
The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is supported by the fact that the number of shares outstanding remains unchanged between basic and diluted shares, indicating no imminent threat of share dilution. The company's conservative capital structure and strong liquidity position further mitigate financial risks.
Recent events and filings do not indicate any significant changes in the company's operations or financial status. The company continues to operate within its established business model, with no major strategic shifts or new product launches reported in the latest filings.
- The company has a strong liquidity position, as evidenced by a high current ratio and substantial cash reserves.
- The company's profitability metrics, including return on equity and return on assets, are robust and indicate efficient use of resources.
- The company's capital structure is conservative, with a low debt-to-equity ratio, reducing financial risk.
- The company's growth is supported by strong operating and free cash flows, although there is no significant investment in new assets.
- The company's risk profile is low, with no immediate liquidity or dilution concerns.
- **margin_outlook_rationale**: The company's operating margin is expected to remain stable due to consistent revenue and controlled operating expenses.
- **rd_outlook_rationale**: The company is not currently investing heavily in research and development, as indicated by the negative capital expenditure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 9604.SE Market data — financials · 2026-05-27